Acylated Flavonoid from Vaccinium Corymbosum (Ericaceae) Flowers with Yeast α-Glucosidase Inhibitory Activity
Abstract
Purpose: To isolate and identify chemical constituents with yeast α-glucosidase inhibitory activity from the methanol extract of V. myrtillus (blueberry) flowers.
Methods: The active fraction (ethyl acetate extract) were chromatographed on C18 MPLC column, Sephadex LH-20 column and semi-preparative HPLC column. The isolated compounds were identified by the extensive 1H-nuclear magnetic resonance spectroscopy (NMR), 13C-NMR, 2D-NMR and high resolution mass spectral (HR-MS) analyses.
Results: Two phenolic compounds, an acylated flavonoid and a coumaric acid derivative, were isolated and identified as isorhamnetin-3-O-(6''-O-coumaroyl)-β-D-glucoside (1) and cis-cinnamic acid methyl (2). Compound 1 showed powerful α-glucosidase inhibitory activity and in this regard, was superior to the positive drug, acarbose.
Conclusion: Compounds 1 and 2 were isolated for the first time from this species and the genus of Vaccinium. This is the first report on characterization of these phenolic compounds and the possible utilization of blueberry flowers for nutraceutical and functional food applications.
Keywords: Vaccinium corymbosum, Blueberry, Acylated flavonoid, Yeast α-Glucosidase, Inhibitory activity, Nutraceuticals
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
